大数据助力肝胆恶性肿瘤诊疗探索

肝癌电子杂志 ›› 2020, Vol. 7 ›› Issue (2): 52-55.

大数据助力肝胆恶性肿瘤诊疗探索

卢姗姗, 贾晓东, 张宁, 曾珍, 陆荫英^*

中国人民解放军总医院第五医学中心肝脏肿瘤诊疗与研究中心,北京 100039

收稿日期:2020-01-15 出版日期:2020-06-30 发布日期:2020-07-23
通讯作者: ^* 陆荫英 E-mail: luyinying1973@163.com
作者简介:陆荫英,教授,中国人民解放军总医院第五医学中心肝脏肿瘤诊疗与研究中心。
基金资助:
国家科技重点专项（2017YFC0908401）; 国家科技重大专项（2018ZX10723204-007-002）; 北京市科技计划（Z181100001718075 ）

Exploration on diagnosis and treatment of hepatobiliary malignancies by big data

Lu Shanshan, Jia Xiaodong, Zhang Ning, Zeng Zhen, Lu Yinying^*

Comprehensive Liver Cancer Center, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China

Received:2020-01-15 Online:2020-06-30 Published:2020-07-23

摘要/Abstract

摘要： 肝胆恶性肿瘤是消化系统中比较常见的一类疾病,其发病隐匿,进展速度快,尤其是进展到晚期的肝胆恶性肿瘤,其低根治率和高死亡率仍是临床上比较棘手的主要问题之一。近年来,随着大数据时代的悄然崛起,精准诊疗计划的不断推进,一些新的临床决策、诊疗策略也大量涌现。在肝胆恶性肿瘤领域,大数据与精准医疗的完美结合,将有利于众多医学者更加深入、全面地了解肝胆恶性肿瘤的生物学特点,进而揭示肝胆恶性肿瘤的驱动基因和发病机制;大数据的整合分析,也会推动个体化、精确化医疗的实施,进而提高临床肝胆恶性肿瘤的规范化诊疗水平,为突破晚期肝胆恶性肿瘤治疗瓶颈带来新的曙光和希望。

关键词: 大数据, 精准医学, 肝胆恶性肿瘤, 个体化治疗

Abstract: Hepatobiliary malignancies are common in digestive system diseases, which are occult and develop rapidly, especially in advanced hepatobiliary malignancies, it's low radical cure rate and high mortality are still one of the most difficult problems in clinical practice. In recent years, with the rise of big data and the advancement of accurate diagnosis and treatment plan, a number of new clinical decisions and treatment strategies have emerged. In the field of hepatobiliary malignancies, the perfect combination of big data and precision medicine will help many medical scholars to understand the biological characteristics of hepatobiliary malignancies more deeply and comprehensively, and then reveal the driving genes and pathogenesis of hepatobiliary malignancies; The integration and analysis of big data will also promote the implementation of individualized and precision medicine, and improve the standardized diagnosis and treatment level of hepatobiliary malignancies. In addition, it can also bring new light and hope for breaking through the bottleneck of treatment of advanced hepatobiliary malignancies.

Key words: Big data, Precision medicine, Hepatobiliary malignancies, Individualized medicine

卢姗姗, 贾晓东, 张宁, 曾珍, 陆荫英. 大数据助力肝胆恶性肿瘤诊疗探索[J]. 肝癌电子杂志, 2020, 7(2): 52-55.

Lu Shanshan, Jia Xiaodong, Zhang Ning, Zeng Zhen, Lu Yinying. Exploration on diagnosis and treatment of hepatobiliary malignancies by big data[J]. Electronic Journal of Liver Tumor, 2020, 7(2): 52-55.

参考文献

[1] PATEL T.Cholangiocarcinoma-controversies and challenges[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(4):189-200.
[2] CHOW PKH, GANDHI M, TAN SB, et al.SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma[J]. J Clin Oncol, 2018, 36(19):1913-1921.
[3] VALLE JW, WASAN H, JOHNSON P, et al.Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumors: a multicentre randomised phase II study-the UK ABC-01 study[J]. Br J Cancer, 2009, 101(4):621-627.
[4] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
[5] ESO Y, MARUSAWA H.Novel approaches for molecular targeted therapy against hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(8):597-607.
[6] COLLINS FS, GREEN ED, GUTTMACHER AE, et al.A vision for the future of genomics research[J]. Nature, 2003, 422(6934):835-847.
[7] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[8] VILLANUEVA A.Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
[9] TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[10] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30.
[11] SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[12] LIU M, JIANG LX, GUAN XY.The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update[J]. Protein Cell, 2014, 5(9):673-691.
[13] POGRIBNY IP, RUSYN I.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J]. Cancer Lett, 2014, 342(2):223-230.
[14] ALLY A, BALASUNDARAM M, CARLSEN R, et al.Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma[J]. Cell, 2017, 169(7):1327-1341.
[15] SCHULZE K, IMBEAUD S, LETOUZE E, et al.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47(5):505-511.
[16] TOTOKI Y, TATSUNO K, COVIINGTON KR, et al.Trans-ancestry mutational landscape of hepatocellular carcinoma genomes[J]. Nat Genet, 2014, 46(12):1267-1273.
[17] HO DW, Kai AK, Ng IO.TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma[J]. Front Med, 2015, 9(3):322-330.
[18] PENG T, LI ZH, LI DJ, et al.MACC1 promotes angiogenesis in cholang-iocarcinoma by upregulating VEGFA[J]. Onco Targets Ther, 2019, 12:1893-1903.
[19] HOSHIDA Y, VILLANUEVA A, KOBAYASHI M, et al.Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma[J]. N Engl J Med, 2008, 359(19):1995-2004.
[20] HOSHIDA Y, VILLANUEVA A, SANGIOVANNI A, et al.Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis[J]. Gastroenterology, 2013, 144(5):1024-1030.
[21] KING LY, CANASTO-CHIBUQUE C, JOHNSON KB, et al.A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration[J]. Gut, 2015, 64(8):1296-1302.
[22] 王晓云, 李林峰, 郭佺, 等. 肝胆肿瘤疾病智能化诊疗模式的发展及启示[J].临床肝胆病杂志, 2019, 35(10):2360-2364.
[23] JIA XD, LU SS, ZENG Z, et al.Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcino-ma[J]. Hepatology, 2020, 71(3):893-906.
[24] XUE RD, CHEN L, ZHANG C, et al.Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes[J]. Cancer Cell, 2019, 35(6):932-947.
[25] COLLINS FS, VARMUS H.A new initiative on precision medicine[J]. N Engl J Med, 2015, 372(9):793-795.
[26] REARDON S.Precision-medicine plan raises hopes[J]. Nature, 2015, 517(7536):540.
[27] MA LC, HERNANDEZ MO, ZHAO YM, et al.Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer[J]. Cancer Cell, 2019, 36(4):418-430.
[28] GAO Q, ZHU HW, DONG LQ, et al.Integrated Proteogenomic Characteriza-tion of HBV-Related Hepatocellular Carcinoma[J]. Cell, 2019, 179(5):1240.
[29] WANG C, VEGNA S, JIN HJ, et.al. Inducing and exploiting vulnerabilities for the treatment of liver cancer[J]. Nature, 2019, 574(7777):268-272.
[30] HARADA K, BABA Y, ISHIMOTO T, et al.LINE-1 methylation level and patient prognosis in a database of 208 hepatocellular carcinoma[J]. Ann Surg Oncol, 2015, 22(4):1280-1287.
[31] 陈谦, 仇小强. 基于大数据的肝癌血管侵袭标志物分析[J]. 中华流行病学杂志, 2017, 38(4):522-527.